Compass Therapeutics Inc (NASDAQ: CMPX) has seen a rise in its stock price by 2.42 in relation to its previous close of 2.07. However, the company has experienced a 24.71% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-21 that BOSTON, April 21, 2025 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been dosed in an Investigator Sponsored Trial (IST) to evaluate tovecimig (CTX-009, a DLL4 x VEGF-A bispecific antibody) for the first time in the front-line setting for patients with biliary tract cancer (BTC). The IST is being conducted at The University of Texas MD Anderson Cancer Center.
Is It Worth Investing in Compass Therapeutics Inc (NASDAQ: CMPX) Right Now?
The stock has a 36-month beta value of 1.12. Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CMPX is 87.84M, and at present, short sellers hold a 7.53% of that float. On April 25, 2025, the average trading volume of CMPX was 1.61M shares.
CMPX’s Market Performance
CMPX’s stock has seen a 24.71% increase for the week, with a -2.08% drop in the past month and a -31.61% fall in the past quarter. The volatility ratio for the week is 8.38%, and the volatility levels for the past 30 days are at 14.69% for Compass Therapeutics Inc The simple moving average for the past 20 days is 17.58% for CMPX’s stock, with a 14.18% simple moving average for the past 200 days.
Analysts’ Opinion of CMPX
Many brokerage firms have already submitted their reports for CMPX stocks, with Leerink Partners repeating the rating for CMPX by listing it as a “Outperform.” The predicted price for CMPX in the upcoming period, according to Leerink Partners is $6 based on the research report published on April 02, 2025 of the current year 2025.
Guggenheim, on the other hand, stated in their research note that they expect to see CMPX reach a price target of $12. The rating they have provided for CMPX stocks is “Buy” according to the report published on February 24th, 2025.
Piper Sandler gave a rating of “Overweight” to CMPX, setting the target price at $12 in the report published on February 19th of the current year.
CMPX Trading at -10.20% from the 50-Day Moving Average
After a stumble in the market that brought CMPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.04% of loss for the given period.
Volatility was left at 14.69%, however, over the last 30 days, the volatility rate increased by 8.38%, as shares surge +3.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.92% lower at present.
During the last 5 trading sessions, CMPX rose by +24.71%, which changed the moving average for the period of 200-days by +146.51% in comparison to the 20-day moving average, which settled at $1.80. In addition, Compass Therapeutics Inc saw 46.21% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CMPX starting from GORDON CARL L, who sale 3,571,428 shares at the price of $1.59 back on Apr 09 ’25. After this action, GORDON CARL L now owns 0 shares of Compass Therapeutics Inc, valued at $5,678,571 using the latest closing price.
ORBIMED ADVISORS LLC, the Director of Compass Therapeutics Inc, sale 3,571,428 shares at $1.59 during a trade that took place back on Apr 09 ’25, which means that ORBIMED ADVISORS LLC is holding 0 shares at $5,678,571 based on the most recent closing price.
Stock Fundamentals for CMPX
Current profitability levels for the company are sitting at:
- -15.01 for the present operating margin
- 0.75 for the gross margin
The net margin for Compass Therapeutics Inc stands at -12.93. The total capital return value is set at -0.38. Equity return is now at value -36.07, with -33.22 for asset returns.
Based on Compass Therapeutics Inc (CMPX), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -6.99. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -29.59.
Currently, EBITDA for the company is -48.47 million with net debt to EBITDA at 0.56. When we switch over and look at the enterprise to sales, we see a ratio of 71.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.96.
Conclusion
To sum up, Compass Therapeutics Inc (CMPX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
